Watch ELOX. Know when insiders buy.
One email the day a filing lands. Free.
ELOX
Eloxx Pharmaceuticals, Inc.
15.75
−0.53 −3.26%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $63.6MP/E —DIV YIELD —FCF YIELD —REV TTM $0 −100.0%NET INCOME −$6MNET CASH $61M52W 10.95 – 20.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.5M | −$4.5M | — | -0.66 | −$4.8M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$3.8M | −$3.8M | — | -0.08 | −$5.5M | — | — | Aug 11 |
| Q2 2025 · Jun 30 | — | — | — | −$1.6M | −$1.9M | — | -5.45 | −$1.8M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$1.2M | −$1.7M | — | -0.45 | $1.2M | — | — | Aug 11 |
| Q4 2023 · Dec 31derived | — | — | — | −$4M | −$2.9M | — | -0.67 | −$2M | — | — | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | −$3.6M | −$3.6M | — | -1.31 | −$3.5M | $0 | −$3.5M | Nov 13 |
| Q2 2023 · Jun 30 | — | — | — | −$4.1M | −$4.3M | — | -1.96 | −$2.1M | $0 | −$2.1M | Nov 13 |
| Q1 2023 · Mar 31 | — | — | — | −$5.5M | −$6.2M | — | -2.88 | −$6.8M | $0 | −$6.8M | Nov 13 |
| Q4 2022 · Dec 31derived | — | — | — | −$6M | −$6.3M | — | -2.92 | −$5.7M | $0 | −$5.7M | Mar 31 |
| Q3 2022 · Sep 30 | — | — | — | −$7.1M | −$7.5M | — | -3.47 | −$6.9M | $48K | −$7M | Nov 13 |
| Q2 2022 · Jun 30 | — | — | — | −$10.3M | −$10.6M | — | -4.90 | −$9.7M | $7K | −$9.8M | Nov 13 |
| Q1 2022 · Mar 31 | — | — | — | −$11M | −$11.6M | — | -5.36 | −$9.5M | $11K | −$9.5M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$6.4M | −$6M | — | -0.49 | −$6.3M | — | — | — | — |
| FY2024 · to Dec 31 | $6.4M | — | −$2.5M | −$3.1M | -49.4% | -0.84 | −$4.7M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$17.3M | −$17.1M | — | -6.63 | −$14.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$34.4M | −$36.1M | — | -16.65 | −$31.8M | $66K | −$31.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$66M | −$66.7M | — | -38.15 | −$35M | $89K | −$35.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$33.5M | −$34.6M | — | -0.86 | −$28.2M | — | — | — | — |
Every number comes from Eloxx Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.